Eli Lilly and Company Limited

Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL
Telephone: +44 (0)1256 315 000
Fax: +44 (0)1256 775 858
WWW: http://www.lilly.co.uk
Medical Information e-mail: ukmedinfo@lilly.com
Customer Care direct line: +44 (0)1256 315 999
Medical Information Fax: +44 (0)1256 775 569
Patient Information Leaflet last updated on the eMC: 25/08/2009
PIL Celance 50, 250 microgram and 1 mg tablets.

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 25/08/2009 and displayed until Current
Reasons for adding or updating:
  • Change/addition of instructions for reconstitution and/ or administration
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change of contra-indications
Updated on 26/06/2009 and displayed until 25/08/2009
Reasons for adding or updating:
  • Change to date of revision
  • Change due to user-testing of patient information
Updated on 02/03/2009 and displayed until 26/06/2009
Reasons for adding or updating:
  • Change to date of revision
  • Change due to user-testing of patient information
Updated on 27/10/2008 and displayed until 02/03/2009
Reasons for adding or updating:
  • Change to date of revision
  • Change due to user-testing of patient information
Updated on 02/05/2008 and displayed until 27/10/2008
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 11/01/2008 and displayed until 02/05/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to Marketing Authorisation Holder
  • Change to manufacturer contact details
  • Change to date of revision
Updated on 05/02/2007 and displayed until 11/01/2008
Reasons for adding or updating:
  • Change due to harmonisation of patient information leaflet
  • Change to date of revision
Updated on 07/08/2006 and displayed until 05/02/2007
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 04/02/2005 and displayed until 07/08/2006
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision
Updated on 24/09/2004 and displayed until 04/02/2005
Reasons for adding or updating:
  • Change to side-effects
Updated on 13/01/2003 and displayed until 24/09/2004
Reasons for adding or updating:
  • Update to PIL
Updated on 26/04/2001 and displayed until 13/01/2003
Reasons for adding or updating:
  • No reasons supplied
Updated on 03/08/2000 and displayed until 26/04/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   pergolide mesilate


© 2009 Datapharm Communications Ltd

Go to www.medicines.org.uk